TerryWhite Chemmart community delivers in the fight against ovarian cancer

For nearly twenty years, the TerryWhite Chemmart network has been dedicated to raising funds and awareness in support of their primary charity partner, Ovarian Cancer Australia. Earlier this week, Acting CEO Christine Dixon accepted a cheque for $434,000 from the brand, marking the culmination of a year’s worth of fundraising efforts.

Ovarian cancer is the deadliest cancer for women and those with ovaries, with a five-year survival rate of just 49%. There is no early detection test, and a common misconception is that cervical screening (pap-smear) tests for ovarian cancer.

Ovarian Cancer Australia exists to ensure that no one suffering from ovarian cancer walks alone. The entire TerryWhite Chemmart network has been committed to raising much-needed funds and awareness through various activities, including auctions, morning ‘teal’s’, raffles, treks and swims, as well as the sale of teal-coloured merchandise across the pharmacy network.

In the last two years, the TWC Supplier Partner community has also rallied to support a broader fundraising campaign, which this year expanded to 25 suppliers and over 170 products, with 50 cents from the sale of each product being donated to the cause.

Reflecting on the efforts to help change the trajectory for those suffering from this disease, Executive General Manager Nick Munroe said, “We can all do our part, and it is incredible that across our pharmacy, customer and supplier network, everyone has had the opportunity to contribute to raising such an incredible amount for Ovarian Cancer Australia.”

“Ovarian Cancer Australia has been our primary charity partner for nearly 20 years, and we are proud to support them in the work they do. None of this would be possible without the dedication of our Network and Supplier Partners, and for that, we thank them,” he continued.

Acting CEO Christine Dixon added, “On behalf of Ovarian Cancer Australia and our community, we are deeply grateful to our longstanding partner of 19 years, TerryWhite Chemmart. Their commitment to this cause inspires us and brings hope to countless women and their loved ones.”

“With the generous support of the TerryWhite Chemmart network and their supplier partners, their remarkable contribution of $434,000 last financial year will significantly enhance our ability to continue our vital work, ensuring no one affected by ovarian cancer walks alone,” Ms Dixon continued.

TerryWhite Chemmart looks forward to celebrating 20 years of partnership with OCA in 2025, continuing to raise much-needed funds and awareness.

Ovarian Cancer Australia received a cheque for $434,000 from TerryWhite Chemmart during the brand’s annual Supplier Forum 20 July 2024 in Melbourne.

 ABOUT OVARIAN CANCER AUSTRALIA
Ovarian Cancer Australia is an independent national not-for-profit organisation, supporting women diagnosed with ovarian cancer. Their focus is to provide care and support for those affected by ovarian cancer; and represent them by leading change. Their vision is to save lives and ensure no woman with ovarian cancer walks alone. We were founded in 2001 by a group of people who had been affected by ovarian cancer, either themselves or through a loved one. Ovarian Cancer Australia is a member of the World Ovarian Cancer Coalition, which works to raise awareness of ovarian cancer on a global scale.

Visit www.ovariancancer.net.au 

ABOUT TERRYWHITE CHEMMART
TerryWhite Chemmart is one of Australia’s leading retail pharmacy networks delivering frontline healthcare. With 600 community pharmacies across Australia, we are committed to ensuring every Australian has easier access to pharmacists and expert health advice every day. TerryWhite Chemmart provides high-quality, accessible, and cost-effective community-based health care services and programs.

Visit www.terrywhitechemmart.com.au

Must Read

New regional roadmaps for prioritising antimicrobial resistance

0
A new publication by the International Pharmaceutical Federation (FIP) identifies priority actions pharmacists should take to minimise antimicrobial resistance (AMR). The publication presents six...